Bradley Pharmaceuticals, Inc.

Euro-celtique S.a.

Penwest Pharmaceuticals Company

Edward Mendell Co., Inc.

Dileep Bhagwat

Daniel Glassman

Bradley P Glassman

Anand R Baichwal

Donald Diehl, Ii

Benjamin Oshlack

Mark Chasin

Richard S Sackler

Frank Pedi, Jr

Oliver Iny

Brad P Glassman

Topical compositions which include urea and an antimicrobial agent, particularly sulfacetamide or metronidazole, are described. Sulfacetamide compositions further including sulfur are also described. Methods for treating dermatological disorders using the compositions are also described.

Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use

Topical compositions which include urea and an antimicrobial agent, particularly sulfacetamide, are described. Sulfacetamide compositions further including sulfur are also described. Methods for treating dermatological disorders using the compositions are also described.

Methods of treating fungal conditions and onychomycosis are described which include administration of a safe and effective amount of urea in a topical formulation to an affected area on the skin or around a nail of a patient in need of treatment.

Method of treating fungal conditions of the skin

Topical compositions which include urea and carbamide peroxide are described. Compositions having a pH in the acidic range, particularly in the range of about 2.5 to about 9 are also described. Methods for treating dermatological disorders using the composition are also described.

Carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use

This invention is directed to a novel solid matrixed controlled release, oral dosage form where the dosage form contains a therapeutically effective amount of a sulfonylurea or a salt or derivative thereof in the matrix. Further, the use of an aqueous alkalizing medium affords substantially complete bioavailability of the drug from the matrix of the tablet. The core tablets may optionally be coated with a coating material in the range of 2% to 10% with an enteric material or with a water insoluble material like ethyl cellulose.

Once-a-day controlled release sulfonylurea formulation

Described are dermatological compositions for treating, protecting and re-epitheliazing cutaneous wounds and damaged skin, such compositions including about 21 to about 40% urea and trace amounts of zinc, copper and manganese in the form of their respective pharmaceutically acceptable salts.

Dermatological composition containing urea

A method of treating onychomycosis is described which includes administration of a topical formulation containing an effective amount of urea and an antioxidant to an infected area around a nail of a patient.

Method of treating onychomycosis with urea and an antioxidant

A method of treating onychomycosis is described which includes administration of an effective amount of urea in a topical formulation to an infected area around a nail of a patient.

Method of treating onychomycosis

Disclosed are compositions of a novel astringent and keratolytic topical pharmaceutical base into which drugs can be incorporated such as for example an anti-pruritic drug and/or an anti-inflammatory drug.

Topical pharmaceutical base with anti-pruritic and/or anti-inflammatory drugs

Novel topical formulations an anti-microbially effective amount of povidone iodine and a water-washable emollient, as well as, methods for their preparation, are disclosed.

Emollient antimicrobial formulations containing povidone iodine

Povidone-Iodine (PVP-I) solutions stable according to U.S.P. standards and a method for preparing the same are disclosed. The PVP-I solution includes a microbicidal effective amount of available iodine and an alkalinizing agent in an effective amount to maintain the stability of the solution for a desired shelf-life of the solution when said solution is stored in a substantially nonpermeable container, the solution being non-buffered. In preferred embodiments, the iodophor solution is a microbicidal PVP-I solution for ophthalmic use.

Growing community of inventors

Bronxville, NY, United States of America

Dileep Bhagwat